UPB

1.63518.25%
DB

Daniella Beckman

Lead Independent Director

Ms. Daniella Beckman, C.P.A., serves as an Independent Director at Upstream Bio, Inc. since October 2024. She served as Independent Director at Blueprint Medicines Corporation since December 08, 2021 until July 18, 2025. She served as Chief Financial Officer of Tango Therapeutics, Inc. since September 2019 until April 15, 2026 and served as Interim Chief Financial Officer from October 2016 to August 2019. She had been an Independent Director at 5:01 Acquisition Corp. since October 2020 until October 2022. She provided consulting and Interim Chief Financial Officer services for early-stage biotechnology companies through Beckman Consulting LLC from November 2015 to September 2019. She served as the Chief Financial Officer of Neon Therapeutics Inc. from May 17, 2016 to July 5, 2017. She joined Neon Therapeutics in November 2015 as part-time Chief Financial Officer. She led the finance functions and strategic financial planning. She has of financial and operational experience working with private and publicly traded biotechnology companies. With strategic and operational expertise, she focuses on building financial infrastructure and leading financial functions, including strategic financial planning. She served as the Chief Financial Officer and Treasurer at Idenix Pharmaceuticals, Inc., from June 2, 2011 to August 2014 and served as its Principal Accounting Officer. She served as Senior Vice President of Idenix Pharmaceuticals Inc., since June 2012. She served as Vice President at Idenix Pharmaceuticals Inc., from June 2, 2011 to June 2012. She served as Interim Chief Financial Officer and Interim Treasurer of Idenix Pharmaceuticals from October 2010 to June 2, 2011. She served as the Corporate Controller of Idenix Pharmaceuticals from March 2008 to October 2010. From March 2006 to March 2008, she held positions at Coley Pharmaceutical Group, Corporate Controller. She is Director at Vor Biopharma Inc. since July 2020 and serves as its Lead Director since March 2026. Prior to Coley, she held positions at Biogen Idec from September 2004 to March 2006 as well as PricewaterhouseCoopers from September 2000 to 2004. She had been an Independent Director of Translate Bio, Inc. since October 4, 2017 until September 2021. Ms. Beckman holds a B.S. in business administration/accounting from Boston University and is a certified public accountant in Massachusetts.

Positions